Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 13 | 2025 | 671 | 2.590 |
Why?
|
| Erectile Dysfunction | 2 | 2021 | 26 | 1.470 |
Why?
|
| Analgesics, Opioid | 4 | 2025 | 532 | 1.320 |
Why?
|
| Hypoglycemia | 2 | 2017 | 67 | 1.020 |
Why?
|
| Pre-Eclampsia | 2 | 2023 | 72 | 0.930 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 214 | 0.920 |
Why?
|
| Pregnancy in Adolescence | 3 | 2013 | 24 | 0.910 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 687 | 0.850 |
Why?
|
| Pressure Ulcer | 1 | 2023 | 35 | 0.810 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2021 | 7 | 0.740 |
Why?
|
| Depression, Postpartum | 3 | 2023 | 132 | 0.710 |
Why?
|
| Diabetes, Gestational | 1 | 2023 | 141 | 0.700 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 330 | 0.660 |
Why?
|
| Hypertension | 2 | 2022 | 590 | 0.640 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6486 | 0.630 |
Why?
|
| United States | 16 | 2025 | 7696 | 0.610 |
Why?
|
| Pregnancy Outcome | 3 | 2023 | 192 | 0.580 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 535 | 0.570 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 208 | 0.560 |
Why?
|
| Electronic Health Records | 2 | 2021 | 355 | 0.560 |
Why?
|
| Sulfonylurea Compounds | 1 | 2017 | 13 | 0.560 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 25 | 0.560 |
Why?
|
| Weight Gain | 1 | 2017 | 168 | 0.510 |
Why?
|
| Pain | 4 | 2023 | 405 | 0.480 |
Why?
|
| Intention | 2 | 2012 | 69 | 0.470 |
Why?
|
| Blood Glucose | 2 | 2018 | 484 | 0.460 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 5390 | 0.460 |
Why?
|
| Humans | 31 | 2025 | 62462 | 0.430 |
Why?
|
| Delirium | 2 | 2025 | 56 | 0.430 |
Why?
|
| Female | 23 | 2025 | 32378 | 0.420 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 2529 | 0.420 |
Why?
|
| Pregnancy, Unwanted | 1 | 2012 | 10 | 0.410 |
Why?
|
| Pregnancy, Unplanned | 1 | 2012 | 22 | 0.400 |
Why?
|
| Risk Assessment | 3 | 2016 | 2033 | 0.400 |
Why?
|
| Algorithms | 2 | 2022 | 1003 | 0.390 |
Why?
|
| Male | 17 | 2025 | 29368 | 0.390 |
Why?
|
| Pregnancy | 9 | 2023 | 2308 | 0.390 |
Why?
|
| Aged | 14 | 2025 | 14203 | 0.380 |
Why?
|
| Tretinoin | 1 | 2011 | 51 | 0.360 |
Why?
|
| Behavioral Symptoms | 2 | 2021 | 16 | 0.350 |
Why?
|
| Prevalence | 5 | 2023 | 1343 | 0.350 |
Why?
|
| Pain Management | 2 | 2024 | 162 | 0.350 |
Why?
|
| Cohort Studies | 6 | 2023 | 2530 | 0.340 |
Why?
|
| Carcinoma | 1 | 2011 | 124 | 0.340 |
Why?
|
| Mothers | 1 | 2013 | 275 | 0.330 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 831 | 0.320 |
Why?
|
| Premature Birth | 2 | 2022 | 112 | 0.290 |
Why?
|
| Infant, Newborn | 5 | 2023 | 1335 | 0.270 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 413 | 0.250 |
Why?
|
| Young Adult | 7 | 2024 | 4610 | 0.240 |
Why?
|
| Skin Ulcer | 1 | 2025 | 15 | 0.230 |
Why?
|
| Social Participation | 1 | 2025 | 16 | 0.230 |
Why?
|
| Patient Care Planning | 1 | 2025 | 86 | 0.230 |
Why?
|
| Adult | 8 | 2024 | 16567 | 0.230 |
Why?
|
| Delayed-Action Preparations | 1 | 2025 | 115 | 0.230 |
Why?
|
| Risk Factors | 4 | 2023 | 5288 | 0.220 |
Why?
|
| Accidental Falls | 1 | 2025 | 128 | 0.210 |
Why?
|
| Fractures, Bone | 1 | 2025 | 142 | 0.210 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2023 | 11 | 0.210 |
Why?
|
| Suppuration | 1 | 2023 | 12 | 0.210 |
Why?
|
| Family | 1 | 2025 | 240 | 0.210 |
Why?
|
| Ulcer | 1 | 2023 | 14 | 0.210 |
Why?
|
| Arthritis, Psoriatic | 1 | 2023 | 33 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 860 | 0.200 |
Why?
|
| Rhode Island | 2 | 2013 | 99 | 0.200 |
Why?
|
| Pain Measurement | 2 | 2021 | 339 | 0.200 |
Why?
|
| Spondylarthritis | 1 | 2023 | 40 | 0.200 |
Why?
|
| Perinatal Death | 1 | 2022 | 5 | 0.190 |
Why?
|
| Tadalafil | 1 | 2021 | 2 | 0.190 |
Why?
|
| Drug Utilization | 2 | 2021 | 210 | 0.190 |
Why?
|
| Carbolines | 1 | 2021 | 9 | 0.190 |
Why?
|
| Prescription Drug Misuse | 1 | 2022 | 21 | 0.190 |
Why?
|
| Chronic Pain | 1 | 2024 | 150 | 0.190 |
Why?
|
| Neuralgia | 1 | 2021 | 22 | 0.190 |
Why?
|
| Nitrates | 1 | 2021 | 22 | 0.190 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 220 | 0.180 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2022 | 38 | 0.180 |
Why?
|
| Prenatal Care | 2 | 2013 | 173 | 0.180 |
Why?
|
| Logistic Models | 3 | 2013 | 1272 | 0.180 |
Why?
|
| Depressive Disorder | 1 | 2023 | 285 | 0.170 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 775 | 0.170 |
Why?
|
| Middle Aged | 7 | 2025 | 17294 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2021 | 5554 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2020 | 48 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 171 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 123 | 0.170 |
Why?
|
| Homes for the Aged | 1 | 2021 | 157 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 294 | 0.160 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2023 | 331 | 0.160 |
Why?
|
| Anticonvulsants | 1 | 2020 | 104 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 162 | 0.160 |
Why?
|
| Epilepsy | 1 | 2020 | 110 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 168 | 0.150 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 38 | 0.140 |
Why?
|
| Medicare | 4 | 2023 | 614 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 67 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2021 | 493 | 0.140 |
Why?
|
| Immunization | 1 | 2016 | 133 | 0.130 |
Why?
|
| Adolescent | 4 | 2018 | 6147 | 0.120 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2015 | 31 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2638 | 0.120 |
Why?
|
| Vaccines | 1 | 2016 | 95 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 716 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2439 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 654 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 706 | 0.110 |
Why?
|
| Time Factors | 2 | 2024 | 3737 | 0.110 |
Why?
|
| Insulin | 1 | 2018 | 687 | 0.110 |
Why?
|
| Heart Failure | 1 | 2021 | 899 | 0.110 |
Why?
|
| Maternal Age | 1 | 2013 | 34 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1359 | 0.100 |
Why?
|
| Maternal Behavior | 1 | 2013 | 32 | 0.100 |
Why?
|
| Family Planning Services | 1 | 2012 | 22 | 0.100 |
Why?
|
| Prognosis | 1 | 2017 | 1716 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1537 | 0.100 |
Why?
|
| Risk-Taking | 1 | 2012 | 162 | 0.090 |
Why?
|
| Biomarkers | 1 | 2017 | 1379 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2011 | 52 | 0.090 |
Why?
|
| Keratinocytes | 1 | 2011 | 65 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 193 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 370 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 376 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1076 | 0.080 |
Why?
|
| Career Choice | 1 | 2011 | 128 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2011 | 738 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1552 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1636 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 1117 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2011 | 534 | 0.070 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 108 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2023 | 103 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 95 | 0.050 |
Why?
|
| Perinatal Care | 1 | 2023 | 65 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2023 | 392 | 0.050 |
Why?
|
| Stillbirth | 1 | 2022 | 18 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 173 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2021 | 34 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 968 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2021 | 20 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 70 | 0.040 |
Why?
|
| Analgesics | 1 | 2021 | 102 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 851 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 20 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 768 | 0.040 |
Why?
|
| Medicare Part D | 1 | 2020 | 37 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2021 | 220 | 0.040 |
Why?
|
| Child | 2 | 2023 | 4429 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 70 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 861 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 299 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 883 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2016 | 46 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 156 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 2015 | 24 | 0.030 |
Why?
|
| Data Collection | 1 | 2016 | 384 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1216 | 0.030 |
Why?
|
| Education | 1 | 2011 | 69 | 0.020 |
Why?
|
| Goals | 1 | 2011 | 91 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 505 | 0.020 |
Why?
|